|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01DI02
|
|
gptkbp:brand
|
gptkb:Teflaro
|
|
gptkbp:CASNumber
|
400827-46-5
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:drugClass
|
fifth-generation cephalosporin
|
|
gptkbp:effect
|
gptkb:Streptococcus_pneumoniae
gptkb:methicillin-resistant_Staphylococcus_aureus
gptkb:Bacteria
gptkb:Klebsiella_pneumoniae
|
|
gptkbp:eliminationHalfLife
|
2.6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C22H21N8O8PS4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ceftaroline fosamil
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
hydrolysis to ceftaroline
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prodrugOf
|
gptkb:ceftaroline
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
pruritus
rash
|
|
gptkbp:usedFor
|
bacterial infections
community-acquired pneumonia
acute bacterial skin and skin structure infections
|
|
gptkbp:bfsParent
|
gptkb:Zinforo
gptkb:ceftaroline
|
|
gptkbp:bfsLayer
|
7
|